CLINICAL TRIALS PROFILE FOR AVINZA
✉ Email this page to a colleague
All Clinical Trials for Avinza
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00488969 ↗ | Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury | Completed | U.S. Department of Education | Phase 2 | 2007-07-01 | We would like to learn if a medicine called "modified-release morphine sulfate" (Avinza) helps reduce Spinal Cord Injury (SCI)-related pain that has lasted a long time. "Modified-release" means that the medicine in the capsules is slowly released to the body, instead of being released all at once. Avinza is approved by the Food and Drug Administration for the treatment of pain, but we do not know how effective Avinza is in reducing SCI-related pain. |
| NCT00488969 ↗ | Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury | Completed | Icahn School of Medicine at Mount Sinai | Phase 2 | 2007-07-01 | We would like to learn if a medicine called "modified-release morphine sulfate" (Avinza) helps reduce Spinal Cord Injury (SCI)-related pain that has lasted a long time. "Modified-release" means that the medicine in the capsules is slowly released to the body, instead of being released all at once. Avinza is approved by the Food and Drug Administration for the treatment of pain, but we do not know how effective Avinza is in reducing SCI-related pain. |
| NCT00640042 ↗ | Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza | Completed | Pfizer | Phase 4 | 2008-03-01 | The purpose of this study is to provide information in a broad, "real world" population of chronic pain patients assessing both pain control with AVINZA as well as the potential risk for misuse and abuse. |
| NCT00782548 ↗ | Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults | Completed | Actavis Inc. | Phase 4 | 2004-05-01 | The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary objective of this study was to evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations |
| NCT00782548 ↗ | Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults | Completed | Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | Phase 4 | 2004-05-01 | The primary objective of this study was to compare the single-dose relative bioavailability of Alpharma Branded Products Division (Kadian®) and Ligand® Pharmaceuticals Inc. (AVINZA®) 30 mg morphine sulfate sustained-release capsules in healthy adult volunteers under fed conditions. The secondary objective of this study was to evaluate the adverse events associated with each of these 2 different morphine sulfate modified-release commercial formulations |
| NCT00994383 ↗ | Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release | Completed | Roxane Laboratories | N/A | 2007-01-01 | Characterize the steady-state pharmacokinetics of morphine after oral administration of Roxane Laboratories' morphine sulfate immediate release tablets and oral solution and to compare their pharmacokinetics to that of AVINZA. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Avinza
Condition Name
Clinical Trial Locations for Avinza
Trials by Country
Clinical Trial Progress for Avinza
Clinical Trial Phase
Clinical Trial Sponsors for Avinza
Sponsor Name
